Tazoral Risk Management Plan Resubmission May Affect Approval Timeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan will resubmit a revised risk management program for Tazoral as a result of the negative review by FDA’s advisory committees. The resubmission could extend the user fee date of the oral retinoid, Allergan says.
You may also be interested in...
Accutane Risk Management Program Changes Held Up By Celgene Patents
Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter